EUVIMEDEUVIMED entdecken
Crossref

Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis

Matthew R LeBlanc, Xi Zhou, Christopher D Baggett, Sascha A Tuchman, Christopher E Jensen, Eben I Lichtman, Samuel M Rubinstein

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Matthew R LeBlanc und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, North Carolina, USA; UNC Lineberger Comprehensive Cancer Center, Chapel H…. Hauptthemen laut MEDLINE: Multiple Myeloma, SEER Program, Medicare. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals since 2012. We characterized population-level trends in RRMM therapy selection, survival and cost outcomes associated with RRMM treatment over time. MATERIALS AND METHODS: Our cohort included adults diagnosed with multiple myeloma (MM) in the SEER-Medicare database from 2007-2017 who received at least one antimyeloma agent. MM-directed therapies and lines of therapy were identified. Changes in 2LT regimens over time were described. Trends in overall survival from 2LT initiation over time were analyzed using a Cox proportional hazards model adjusting for factors associated with survival in MM. Trends in mean inflation-adjusted cost per 12 months of 2LT were analyzed using JoinPoint analysis. RESULTS: A total of 9,822 patients met eligibility criteria, of whom 5,866 (59.7%) received 2LT. By 2018, 46% of 2LT regimens contained at least one agent approved in 2012 or later. Year of 2LT initiation was associated with improved overall survival (HR 0.78 per 5 years, 95% CI 0.74-0.84) after adjustment. Costs associated with 2LT increased over the study period, and the rate of cost increase increased significantly after 2012 (0.89%/year vs. 9.9%/year, P < .001), with higher total costs for regimens containing newer novel agents (mean $224,193 vs. $189,381, P < .001) CONCLUSION: Overall survival after initiation of 2LT has improved, however this has been accompanied by significant increases in costs of RRMM treatment, particularly for patients receiving newer novel agents. These findings provide useful context for existing and future drug approvals in RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaSEER ProgramMedicareHumansMaleFemaleUnited StatesAgedAged, 80 and overAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Health services researchRelapsed refractorySEER-MedicareTreatment patterns

Autor:innen und Institutionen

  • University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, North Carolina, USA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA. Electronic address: matthew_leblanc@unc.edu.
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA; University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

Zitieren

APA

LeBlanc, M. R., Zhou, X., Baggett, C. D., Tuchman, S. A., Jensen, C. E., Lichtman, E. I., & Rubinstein, S. M. (2024). Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.04.005

Vancouver

LeBlanc MR, Zhou X, Baggett CD, Tuchman SA, Jensen CE, Lichtman EI, et al. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.04.005

BibTeX
@article{LeBlanc2024,
  author = {LeBlanc, Matthew R and Zhou, Xi and Baggett, Christopher D and Tuchman, Sascha A and Jensen, Christopher E and Lichtman, Eben I and Rubinstein, Samuel M},
  title = {Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.04.005}
}
Kostenlos starten →